BridgeBio Launches Nationwide ATTR-CM Awareness Campaign Ahead of World Amyloidosis Day
Event summary
- BridgeBio Pharma, Inc. launched a nationwide education effort to increase awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) ahead of World Amyloidosis Day on October 26, 2026.
- The campaign includes an October 6 YouTube premiere featuring Sway Calloway, Howard “H” White, and leading medical and cultural voices.
- The initiative is supported by community partners including the Association of Black Cardiologists (ABC), the National Minority Quality Forum (NMQF), and Hip Hop Public Health (HHPH).
- Approximately 1 in 25 Black Americans carries a genetic variant associated with ATTR-CM, which is often overlooked or diagnosed late.
The big picture
BridgeBio's initiative highlights the critical need for early diagnosis and treatment of ATTR-CM, particularly within the Black American community where genetic variants are more prevalent. The campaign leverages cultural and medical partnerships to bridge the gap between scientific advancements and patient awareness, addressing a significant unmet need in cardiovascular health. This effort aligns with broader industry trends towards personalized medicine and targeted education for genetic diseases.
What we're watching
- Awareness Impact
- How the nationwide education effort will affect early diagnosis rates and patient outcomes for ATTR-CM.
- Community Engagement
- Whether the partnership with cultural and medical leaders will sustain long-term engagement and trust within affected communities.
- Diagnostic Advancements
- The pace at which diagnostic tools and clinical guidelines for ATTR-CM will evolve in response to increased awareness.